Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given “Outperform” Rating at Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report issued on Monday. The firm currently has a $37.00 price objective on the stock, down from their previous price objective of $38.00.

Several other analysts also recently weighed in on the stock. Maxim Group restated a hold rating and set a $35.00 price objective on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. Vetr downgraded shares of Teva Pharmaceutical Industries Limited from a buy rating to a hold rating and set a $31.74 price objective for the company. in a research report on Wednesday, July 12th. BidaskClub downgraded shares of Teva Pharmaceutical Industries Limited from a buy rating to a hold rating in a research report on Tuesday, July 11th. Oppenheimer Holdings, Inc. set a $41.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a buy rating in a research report on Tuesday, June 27th. Finally, Wells Fargo & Company restated a hold rating on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, June 27th. Sixteen investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $42.78.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 0.38% on Monday, reaching $31.95. 5,314,284 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $31.09 and a 200 day moving average of $32.49. The firm has a market capitalization of $32.46 billion, a P/E ratio of 409.62 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a one year low of $27.59 and a one year high of $55.79.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, hitting the consensus estimate of $1.06. The business had revenue of $5.63 billion during the quarter, compared to the consensus estimate of $5.69 billion. Teva Pharmaceutical Industries Limited had a net margin of 1.49% and a return on equity of 16.38%. The company’s revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.20 EPS. On average, equities research analysts predict that Teva Pharmaceutical Industries Limited will post $4.76 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://sportsperspectives.com/2017/07/19/teva-pharmaceutical-industries-limited-nyseteva-given-outperform-rating-at-royal-bank-of-canada.html.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 22nd. Investors of record on Monday, June 5th were paid a $0.34 dividend. The ex-dividend date was Thursday, June 1st. This represents a $1.36 dividend on an annualized basis and a yield of 4.26%. Teva Pharmaceutical Industries Limited’s payout ratio is 5,802.90%.

A number of large investors have recently modified their holdings of TEVA. Guggenheim Capital LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 1.1% in the fourth quarter. Guggenheim Capital LLC now owns 40,276 shares of the company’s stock worth $1,460,000 after buying an additional 446 shares during the last quarter. Lincluden Management Ltd. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 7.8% in the fourth quarter. Lincluden Management Ltd. now owns 58,854 shares of the company’s stock worth $2,133,000 after buying an additional 4,272 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 21.3% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,564,560 shares of the company’s stock worth $165,461,000 after buying an additional 801,106 shares during the last quarter. UBS Asset Management Americas Inc. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 150.7% in the fourth quarter. UBS Asset Management Americas Inc. now owns 2,004,760 shares of the company’s stock worth $72,672,000 after buying an additional 1,205,253 shares during the last quarter. Finally, HighPoint Advisor Group LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 19.3% in the fourth quarter. HighPoint Advisor Group LLC now owns 6,250 shares of the company’s stock worth $219,000 after buying an additional 1,010 shares during the last quarter. 56.26% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply